E Therapeutics (ETX)
ETX Share PerformanceMore
|52 week high||27.2500 20/01/16|
|52 week low||7.0000 22/12/16|
|52 week change||-18.7500 (-69.12%)|
|4 week volume||2,446,968 23/12/16|
Latest News« previous» nextMore
12/01/2017 - 10:38 RNS
RNS Number: 0203U e-Therapeutics plc 12 January 2017 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii e-Therapeutics plc 2 Reason for the notification (please tick t...
09/01/2017 - 07:30 StockMarketWire
e-Therapeutics has appointed Dr. Raymond Barlow as chief executive. He will take up the role on or before 1 May, at which...
09/01/2017 - 07:00 RNS
Notification of any change to a companys board e.g. appointments/resignations/changes to important functions or executive responsibilities of a director
04/01/2017 - 09:45 StockMarketWire
Prof Trevor Jones, Non Executive Director, received in lieu of fees/salary 36,917 shares in the company on the 3rd January...
04/01/2017 - 07:00 RNS
23/11/2016 - 16:21 RNS
RNS Number: 9836P e-Therapeutics plc 23 November 2016 23 November 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Grant of share options and Directors' dealings Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total o...
06/10/2016 - 09:25 StockMarketWire
Prof Trevor Jones, Non Executive Director, bought 41,204 shares in the company on the 5th October 2016 at a price of 11.33p...
06/10/2016 - 09:12 RNS
RNS Number: 8817L e-Therapeutics plc 06 October 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Directors' Dealings and Issue of Equity Oxford and Newcastle, UK, 6 October 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that o n 5 October 2016 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 41,20...
|Dividend yield||0 %|
Equity Research (ETX)
e-Therapeutics (ETX) has appointed a new CEO, Dr Raymond Barlow, who will join the company by 1 May 2017. He brings significant R&D and business development experience, which will be invaluable...
e-Therapeutics (ETX) is focused on driving value in its discovery platform. Costs will be reduced as the 17 product candidates in discovery as of July 2016 have been cut to a core five. Cash of £19....
e-Therapeutics’ strategy has evolved, shifting from investment into its proprietary discovery platform to commercialisation of its 12 preclinical assets and the platform itself. Out-licensing and...
- 1 of 3
Latest discussion posts More
“RNS available at company's website. although seems to be missing in III ...”▼
“RNS out today afternoon. Good operational progress. Not sure if that warrants a steep rise in SP as seen over the last few days, including a further 15% today. But I ...”▼
“Clearly somebody knows something we don't. Would that be called insider trading I wonder.”▼
Codes & Symbols
|Symbols||ETX, LSE:ETX, ETX.L, ETX:LN, LON:ETX, XLON:ETX|